Genetic Variability of Methicillin Resistant <italic>Staphylococcus Aureus</italic> Strains Isolated from Burns Patients

Mehdi Goudarzi; Nobumichi Kobayashi; Ali Hashemi; Maryam Fazeli; Masoumeh Navidinia

doi:10.24171/j.phrp.2019.10.3.08

Osong Public Health Res Perspect > Volume 10(3); 2019

Goudarzi, Kobayashi, Hashemi, Fazeli, and Navidinia: Genetic Variability of Methicillin Resistant Staphylococcus Aureus Strains Isolated from Burns Patients

Original Article

Osong Public Health and Research Perspectives 2019; 10(3): 170-176.

DOI: https://doi.org/10.24171/j.phrp.2019.10.3.08

Genetic Variability of Methicillin Resistant Staphylococcus Aureus Strains Isolated from Burns Patients

Mehdi Goudarzi^a,^*, Nobumichi Kobayashi^b, Ali Hashemi^a, Maryam Fazeli^c, Masoumeh Navidinia^d

^aDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

^bDepartment of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan

^cDepartment of Virology, Pasteur Institute of Iran, Tehran, Iran

^dSchool of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

^*Corresponding author: Mehdi Goudarzi, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, E-mail: gudarzim@yahoo.com

Received: March 14, 2019 Revised: March 25, 2019 Accepted: March 27, 2019

(open-access, http://creativecommons.org/licenses/by-nc-nd/4.0/):

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abstract

Objectives

Staphylococcus aureus is a nosocomial pathogen that provides a major challenge in the healthcare environment, especially in burns units where patients are particularly susceptible to infections. In this study, we sought to determine molecular types of S. aureus isolates collected from burns patients, based on staphylococcal protein A and coagulase gene polymorphisms.

Methods

Antibiotic susceptibility testing of 89 S. aureus strains isolated from burn wounds of patients was assessed using the Kirby-Bauer disk diffusion method. Strains were characterized by spa typing, coa typing, and resistance and toxin gene profiling.

Results

A total of 12 different spa types were identified with the majority being t790 (18%). Panton-Valentine leucocidin encoding genes were identified in spa types t044 (5.6%), t852 (2.2%) and t008 (2.2%). The most commonly detected antibiotic resistance gene was ant (4′)-Ia (60.7%). Ten different coa types were detected and the majority of the tested isolates belonged to coa III (47.2%). All the high-level mupirocin-resistant and low-level mupirocin resistant strains belonged to coa type III.

Conclusion

The present study illustrated that despite the high frequency of coa III and spa t790 types, the genetic background of S. aureus strains in Iranian burns patients was diverse. The findings obtained are valuable in creating awareness of S. aureus infections within burns units.

KeyWords: burn; coagulase; methicillin-resistant Staphylococcus aureus; minimum inhibitory concentration; Staphylococcus aureus

Introduction

Burns patients are at an increased risk of colonization and subsequent infections by nosocomial pathogens due to the disruption of skin protective barrier and reduction of immune responses, which can lead to poor clinical outcomes and increased morbidity and mortality rates [1]. More than 70% of deaths in burns patients results from infection with nosocomial microorganisms. Based on the literature, many pathogens are responsible for infection in burns patients, but it is well established that Staphylococcus aureus, in particular, methicillin-resistant S. aureus (MRSA) strains, are one of the most common nosocomial pathogens of burn wounds [2,3]. They could originate from the patient or transmitted easily by direct (i.e. contaminated hands or droplet) and indirect contact (i.e airborne infection). Many of the published data in Iran indicates that multidrug-resistant (MDR) bacteremia and wound infections are the most important causes of mortality in burns patients [2,4,5]. Our previous study showed that there is a high rate of infection with MRSA in burns patients, which is a serious threat for the individual, and also a hazard to public health. Infection with MDR MRSA in burns patients may increase the economic burden of the healthcare system, and causes limitations to the therapeutic options available for treatment [1–4].

A major concern with managing MRSA infections in burns patients is the lack of awareness of the molecular and resistance patterns of MRSA. Various molecular typing techniques have been employed for S. aureus isolates include pulsed-field gel electrophoresis, staphylococcal cassette chromosome mecA (SCCmec) typing, the accessory gene regulator (agr) typing, the mec-associated hypervariable region (dru), multilocus sequence typing, coagulase (coa) typing, and staphylococcal protein A (spa) typing [6]. Although the pulsed-field gel electrophoresis technique is a standard method, it is acknowledged that polymerase chain reaction based methods such as coa and spa typing due to its cost-benefit, rapidity and high throughput ability could be an effective method for routine typing of MRSA isolates [7,8].

The coagulase protein is genetically and antigenically divergent and is an important virulence factor for S. aureus. Sequence analysis of staphylocoagulase (SC) showed 6 regions including a signal sequence, N-terminal D1 region and D2 region, central region, 27-amino acid-repeat region and C-terminal sequence. Ten main types of SC have been described as a result of sequence diversity in the SC region [8–10].

The staphylococcal protein A (spa) gene contains 3 distinct regions including Fc, X and C regions; typing is based on the number of tandem repeats and the sequence variation in region X of the protein A gene [7]. The distribution of spa types of MRSA strains isolated from different geographical areas of the world, show different patterns [11].

In addition, coa typing is also simple to perform, easily interpreted, and requires minimal laboratory skills and equipment, and therefore could be a useful addition to spa typing for genotyping of S. aureus, including MRSA strains [8,9]. In Iran, there is very little information about the genetic diversity of S. aureus isolated from burns patients, therefore, the present study aimed to determine the resistance pattern, carriage of resistance determinants, and molecular characteristics of MRSA isolates collected from burns patients based on coa and spa gene polymorphism analysis.

Materials and Methods

1. Sampling and data collection

In the current cross-sectional study, 89 S. aureus isolates were investigated from the burn wounds of patients during a 12-month study starting from October, 2016 to November, 2017. The Ethics Committee of Shahid Beheshti University of Medical Sciences (Tehran, Iran) also approved this study (IR.SBMU. MSP.REC.1396.878). Swab sticks and scalpel blades were used for sampling burn wounds with pus and hemorrhaging tissues. Specimens were submitted to the laboratory within 4 hours of collection and were processed immediately. Standard biochemical tests, such as growth on mannitol salt agar, colony morphology on blood agar, and coagulase, DNase, and catalase production assays, were used to identify S. aureus isolates. A PCR assay targeting the S. aureus-specific nuc gene was performed to provide definitive identification of S. aureus isolates [1]. S. aureus isolates were stored at −70°C in Tryptic Soy Broth (TSB, Merck co., Germany) containing 20% glycerol until molecular analysis.

2. Antibacterial susceptibility testing and MRSA screening

S. aureus isolates were tested for in vitro susceptibility to ampicillin, amikacin, gentamicin, clindamycin, erythromycin, tetracycline, linezolid, teicoplanin, rifampicin, and quinupristin-dalfopristin (Mast Diagnostics Ltd, Merseyside, UK) by the disk diffusion method, based on the direction of the Clinical and Laboratory Standards Institute (CLSI) guide [12]. The minimum inhibitory concentration (MIC) for vancomycin and mupirocin was determined by the broth microdilution method in accordance with the CLSI recommendation. The MIC cutoff points for vancomycin based on the CLSI criteria were as follows: resistant, ≥ 16 μg/mL; intermediate, 4–8 μg/mL; and susceptible, ≤ 2 μg/mL. Strains were considered to demonstrate low-level mupirocin resistance (LLMUPR) if the MIC value was between 8–256 μg/mL, and high-level mupirocin resistance (HLMUPR) if the MIC value was ≥ 512 μg/mL. MDR isolates are defined by resistance to 3 or more unique antibiotic classes [1,13]. ATCC29213 and ATCC25923 (S. aureus) were considered as the reference strains for quality control purposes. For MRSA screening, phenotypic growth was investigated around the cefoxitin disc (30 μg) placed on Mueller-Hinton agar plates (Merck, Germany), containing 4% NaCl. PCR was applied for genotypic amplification of mecA genes [12].

3. DNA preparation

Genomic DNA from 24-hour cultures of S. aureus isolates were extracted using the InstaGene Matrix kit (BioRad, Hercules co., CA, USA) based on the manufacturer’s protocols. Briefly, for each sample, lysostaphin (Sigma–Aldrich co., USA) was added at a final concentration of 15μg/mL for cell wall lysis. After extraction, the purity of DNA was assessed using a nanometer.

3.1. Detection of resistance and toxin encoding genes

PCR was performed to determine the presence of resistance (mupA, mecA, erm(A), vanA, msr(A), mupB, erm(B), vanB, msr(B), erm((C), tet(M), aac (6′)-Ie/aph (2″), aph (3′)-IIIa, and ant (4′)-Ia,) and toxin (etb, eta, pvl, tst) encoding genes as described by Rashidi et al [13] and Goudarzi et al [1].

4. Typing of the S. aureus protein A locus

PCR amplification was carried out with specific primers for spa typing as suggested by Harmsen and colleagues [7]. DNA fragments containing the spa gene were purified using the QIAGEN PCR purification kit, and were subjected to DNA sequence analysis and nucleotide sequences on both strands were determined using an ABI Prism 377 automated sequencer (Applied Biosystems, Perkin-Elmer Co., Foster City, CA). Sequence-editing was performed using the Chromas software (Version 1.45, Australia). The edited sequences were assigned to particular spa types according to the guidelines described by a Ridom SpaServer database (http://www.spaserver.ridom.de).

5. Coa typing

Four sets of multiplex PCR reactions were used for assigning SC types (I-X) according to the procedure of Hirose et al [5]. Set A contained primers for identifying SC types I, II, III, IVa, IVb, Va, and VI, while set B contained primers for identifying SC types VII, VIII, and X. Set 3 was used for identifying SC types IX and Vb. SC types IVa and IVb were distinguished using set 4 primers [8].

Results

1. Sampling and antibiotic susceptibility

There were 89 S. aureus strains obtained from burns patients. All the strains under study were confirmed as MRSA due to the presence of the mecA gene as well as phenotypically. The results of antimicrobial susceptibility showed that all the isolates were susceptible to linezolid, teicoplanin, and vancomycin, but resistant to ampicillin. The highest rate of resistance was observed to erythromycin (86.5%), followed by gentamicin (84.2%), tetracycline (65.2%), amikacin (55.1%), clindamycin (51.7%), rifampicin (33.7%), and quinupristin-dalfopristin (25.8%).

The results of the microdilution method showed that 28.1% were resistant to mupirocin. Of these, 12 (13.5%) and 13 (14.6%) were HLMUPR and LLMUPR, respectively. The results of mupirocin MIC showed that 10 had MIC values of 16 μg/mL (40%), 3 had MIC of 32 μg/mL (12%), 11 (44%) had MIC ≥ 512 μg/mL, and 1 (4%) had MIC ≥ 1,024 μg/mL.

The MICs of vancomycin showed 31 (34.8%) isolates had MIC of 0.5 μg/mL, 18 (20.3%) had MIC of 1 μg/mL, 23 (25.8%) had MIC of 2 μg/mL and 17 (19.1%) had MIC of 8 μg/mL. Five different resistant phenotypes were identified among our MRSA isolates. The predominant resistance pattern included resistance to 4 antibiotics (52.8%), followed by 6 antibiotics (15.7%), 8 antibiotics (13.5%), 5 antibiotics (11.3%), and 7 antibiotics (6.7%), simultaneously.

2. Antimicrobial resistance and toxin genes

All MRSA strains in the current study harbored at least 2 antibiotic resistance genes. The most commonly detected antibiotic resistance genes were ant (4′)-Ia (60.7%), aac (6′)-Ie/aph (2″) (55.1%), aph (3′)-IIIa (46.7%), tet(M) (43.8%), erm(A) (29.2%), erm(C) (23.6%), erm(B) (20.2%), msr(B) (18%), msr(A) (13.5%), and mupA (13.5%). vanA, vanB and mupB genes were not detected among tested isolates. Analyzing toxin genes revealed that the most prevalent gene was tst (14; 15.7%), followed by pvl (9; 10.1%), eta (2; 2.2%) and etb (2; 2.2%).

3. spa typing

A total of 12 different spa genotypes were identified. t790 accounting for 18% (16/89 each) was found to be the predominant spa type, followed by t064 (13.5%; 12), t030 (11.3%; 10), t044 (10.1%; 9), t852 (9%; 8), t223 (7.9%; 7), t421 (6.7%; 6), t008 (6.7%; 6), t019 (6.7%; 6), t021 (4.5%; 4), t005 (3.4%; 3), and t10795 (2.2%; 2). PVL (lukS-lukF)-encoding genes were identified in 5 strains (55.6%, 5/9) with spa types t044, 2 strains with t852 (22.2%, 2/9), and 2 strains with t008 (22.2%, 2/9), while tst was identified among spa types t790 (64.3%, 9/14) and t223 (35.7%, 5/14). Of the 13 LLMUPR strains, 11 strains belonged to t790 (84.6%), and 2 strains (15.4%) to t008. spa types t064 (10 isolates; 83.3%) and t008 (2 isolates; 16.7%) were observed among 12 HLMUPR-MRSA strains.

4. SC typing

In the present study, 10 different types were detected and the most common coa type was type III (42; 47.2%) with spa types t790 (16; 18%), t064 (10; 11.2%), t030 (10; 11.2%) and t008 (6; 6.8%). The coa type II was observed in 13 isolates (14.6%) with spa types t019 (5; 5.6%), t044 (4; 4.5%) and t021 (4; 4.5%). The coa type VIII with spa types t852 (5; 5.6%) and t044 (5; 5.6%), were detected in 10 isolates (11.2%). From the 9 isolates with coa type I (10.1%), 4 isolates belonged to t223 (4.5%), 3 isolates to t852 (3.4%), and 2 isolates to t005 (2.2%). Both coa type IVb with spa type t421 and coa type VI with spa types t223 (3.4%) and t421 (1.1%) were detected in 4 isolates (4.5%). coa type Iva were identified in 2 isolates with spa type t10795 (2.2%). Two isolates with spa type t064 (2.2%) and 1 isolate with spa type t421 (1.1%) were found in strains with coa type X (3.4%).

PVL-encoding genes were distributed among coa types I (1 isolate; 1.1%), II (3 isolates; 3.4%), III (2 isolates; 2.2%), and VIII (3 isolates; 3.4%), while tst was identified among coa types I (2 isolates; 2.2%), III (9 isolates; 10.1%), VI (3 isolates; 3.4%). eta and etb were detected in spa types t019 (2.2%) and t030 (2.2%), respectively. Surprisingly, all the LLMUPR and HLMUPR-MRSA strains belonged to coa type III. The characteristics of the 89 MRSA strains isolated from burns patients have been summarized in Table 1.

Discussion

Several studies have revealed different findings of resistance rate of S. aureus isolated from burns patients which may be linked to various bacterial detection methods [10]. Although the prevalence rate of mupirocin-resistant S. aureus strains depends on various geographic areas and/or patient populations, a relatively high prevalence of mupirocin-resistant S. aureus strains (28.1%) was found in this study, which was similar to our previously reported rate from burns patients (28.3%) [1]. These results however, show a different prevalence of mupirocin-resistant S. aureus strains than reported by Abbasi-Montazeri et al (6%) [5], Shahsavan et al (40%) [14] and Saderi et al (2.7%) [15] in Iran. A higher prevalence rate of mupirocin resistance was detected among the isolates examined in this study, compared with that found in Greece (2%) [16], Egypt (17.8%) [17], and France (2.1%) [18]. Given the many factors affecting mupirocin resistance, the high rate of mupirocin resistance among S. aureus strains may be related to type and volume of our clinical samples, geographic or socioeconomic factors, infection control policies in healthcare and burn centers, and unrestricted policies in the use of mupirocin. Likewise, the present study showed that the frequency of HLMUPR (13.5%) was lower than LLMUPR (14.6%). The findings of a study in Egypt showed that 61.5% of mupirocin resistance isolates had the HLMUPR pattern, while low-level resistance was reported in 38.5% of mupirocin-resistant isolates [17].

Antimicrobial susceptibility testing revealed a high prevalence rate of resistance to erythromycin (86.5%), gentamicin (84.2%), tetracycline (65.2%), amikacin (55.1%), and clindamycin (51.7%). This finding is similar to that reported by Ko et al from 12 Asian countries [19]. S. aureus isolates with resistance to vancomycin have emerged in many parts of the world and their prevalence is increasing [20,21], and in accordance with other studies [1,5,13], all the isolates in our study were susceptible to vancomycin.

The predominant resistance genes in this study were ant (4′)-Ia (60.7%), aac (6′)-Ie/aph (2″) (55.1%), and aph (3′)-IIIa (46.7%). Similarly, other researchers showed that aminoglycoside resistance genes are dominant in S. aureus clinical isolates [4,13,22]. In addition, in line with other studies, the prevalence of ant(4′)-Ia gene was higher than that of the 2 other aminoglycoside resistance genes, aac(6′)/aph(2′′) and aph(3′)-IIIa [13]. In a study conducted by Ardic et al [23] to determine aminoglycoside modifying enzyme genes in MRSA strains isolated in Turkey, 50 staphylococci from in-patients were assessed. They reported the majority of the isolates carrying aac (6′)-Ie/aph (2″) (60.5%) and followed ant (4′)-Ia (24%) and aph (3′)-IIIa (8%). This increased rate among the isolates tested could be related to the source of the isolated strains (burn wound), inappropriate use of aminoglycoside in the treatment of serious staphylococcal infections, and horizontal gene transfer among the strains.

The tet(M) gene was the 4^th most detected antibiotic resistance gene among our isolates, and was detected in 43.8% of the strains. The frequency of tet(M) in the study of Rashidi et al on 105 S. aureus strains collected from an intensive care unit was 56.8% [13]. In the Emaneini et al study, this frequency was reported as 32.4% [4].

In the present study, 13.5% of isolates carried the mupA gene and were confirmed as HLMUPR MRSA. This finding is lower than the rates reported by Abbasi-Montazeri et al from Iran (34%) [5], González-Domínguez et al from Spain (27.2%) [24], and is higher than India (5%) [25] and Korea (1.8%) [26]. In general, variations in resistance genes were not unexpected, as these genes are subjected to a high, but variable selective pressure.

The findings in the present study provide insight into the epidemiology of coa and spa types in Iran. There were 89 MRSA strains isolated from burns patients with 10 coa genes identified by multiplex PCR, similar to the results of Afrogh et al [10], who showed 9 different patterns of coa genes among staff nose, and patients’ clinical samples in Iran. The same results were reported by Janwithayanuchit et al [27] from Thailand, and Omar et al [28] from Egypt. Our study has reported that types III, II, I and VIII were the most common, and accounted for 47.2%, 14.6%, 10.1% and 10.1% of the isolates, respectively. Hirose et al [8], using the same primer, showed 7 different types of coa gene. They showed that the majority of MRSA isolates belonged to coa type II (91.9%), followed by type VII (3.9%), type I (1.7%), type Iva (1.1%), types III and X (0.6%) and type VI (0.2%). There were 2 MRSA isolates that were untypeable. The difference in coagulase types was attributed to geographical variation.

The present study reported the existence of t790 as the predominant spa type in 18% of isolates which were all coa type III. The low frequency of t790 in the study was in line with Udo’s study from Kuwait, 2016 [21], and a study conducted by Goudarzi et al [1] who analyzed S. aureus strains isolated from burns patients in Iran (13.2%). More than half of spa t790 isolates in this study were carrying the tst gene (56.3%). LLMUPR was detected in 11 strains with t790 (12.4%). Although, virulence markers and drug resistance patterns in t790 isolates may vary, resistance to mupirocin and tst carriage in t790 isolates has been reported by several investigators [1,20].

In the current study, the second most frequent spa type was t064 (13.5%), distributed in coa types III (11.2%) and X (2.3%). All these strains were carrying the mupA gene and confirmed as HLMUPR strains. In agreement with our study, mupirocin resistance in t064 strains has been reported previously from Nigeria [29], Kuwait [21] and Ireland [20].

The third most common spa type was t030 detected in 11.3% of isolates, that all belonged to coa type III. This finding contrasts with our previous study in burns patients that reported t030 as one of the most common spa types amongst the tested isolates (24.5%) [1]. Similarly, the authors of a study of MRSA in Kuwait reported a low prevalence of spa type t030 (2.7%) [21].

Another spa type in our study was t044 (10.1%; 9 isolates), that of those with 5 of those isolates found to be positive for the pvl encoding gene (55.6%). Of 9 isolates with the t030 spa type, 4 isolates belonged to coa type II (44.4%) and 5 isolates to coa type VIII (55.6%). A review performed by Asadollahi and colleagues in 2018, to determine distribution of the most prevalent spa types among clinical isolates of methicillin-resistant and -susceptible S. aureus, indicated that t044, distributed in 11 countries, was one of the most common spa types [11]. This spa type was also previously reported [30].

In agreement with studies performed in Kuwait [31], and Saudi Arabia [32], PVL-positive, multi-resistant spa type t852 isolates (9%) were found in our survey, pointing to their spread in the Gulf Persian Cooperative Council countries.

In this study, the spa type t223 was found in 7.9% of isolates for the first time in Iran. The resistance and virulence profiles of the t223 isolates (PVL-negative, tst-positive) was similar to t223 isolates reported in S. aureus strains isolated from children and parents in the Gaza Strip [33], and also t223 recovered from healthy individuals in Jordan [34], which may suggest the origin of spa type t223.

The t421 isolates was detected in small numbers, similar to Wang et al [35], who revealed that out of 99 MRSA isolates classified as ST239, 92 were ST239-spa t037 and 4 were ST239-spa t421.

In the present study, spa type t008 was detected at an incidence of 6.7%. The majority of the t008 MRSA isolates were resistant to mupirocin, as has been reported in t008 isolates obtained in Kuwait, the USA, and many European countries [20,21].

The spa type t019 was observed among 6 isolates (6.7%) with 5 isolates belonging to SC II and 1 isolate to SC VII. Two isolates harbored the eta encoding gene and belonged to SC II. spa type t019 has also been reported in the United States, and certain Asian and European countries like Egypt, Japan, Poland, and Taiwan [20]. The findings of the present study are in line with a multicenter study conducted during a 6-year period in 17 countries, that reported a low frequency of spa type t019 (3.6%) among tested isolates [36].

In line with our findings that showed the existence of spa type t021 in 4.5% of isolates, several researchers in Lebanon, Ireland, Romania, and Portugal reported a low frequency of the t021 among MRSA clinical isolates in comparison to other spa types, but not to the same extent [20].

t10795 with SC type IVa accounted for 2.2% of all strains. This was supported by Boswihi’s report from Kuwait [21] that spa type t10795, was one of the spa types associated with the ST772-V, Bengal Bay clone, and was detected in small numbers. The Bengal Bay clone was previously reported in Italy, UK, Kuwait, Malaysia, Saudi Arabia, and UAE [21,35,37].

Conclusion

There were 10 different SCs and the 12 spa types in the present study suggesting infection in burns patients is caused by S. aureus strains harboring different variants of the coa and spa genes. The present study showed the prevalence of coa type III and spa type t790 with a high level of MDR in the burns unit, which highlights the special attention for systematic surveillance and antimicrobial stewardship programs for S. aureus infections within burns patients.

Acknowledgments

This work was supported by the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No.: 13322).

Notes

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

1. Goudarzi M, Bahramian M, Tabrizi MS, et al. Genetic diversity of methicillin resistant Staphylococcus aureus strains isolated from burn patients in Iran: ST239-SCCmec III/t037 emerges as the major clone. Microb Pathog 2017;105:1−7.

2. Emaneini M, Beigverdi R, van Leeuwen WB, et al. Prevalence of methicillin-resistant Staphylococcus aureus isolated from burn patients: a systematic review and meta-analysis. J Glob Antimicrob Resist 2018;12:202−6.

3. Motallebi M, Jabalameli F, Asadollahi K, et al. Spreading of genes encoding enterotoxins, haemolysins, adhesin and biofilm among methicillin resistant Staphylococcus aureus strains with staphylococcal cassette chromosome mec type IIIA isolated from burn patients. Microb Pathog 2016;97:34−7.

4. Emaneini M, Bigverdi R, Kalantar D, et al. Distribution of genes encoding tetracycline resistance and aminoglycoside modifying enzymes in Staphylococcus aureus strains isolated from a burn center. Ann Burns Fire Disasters 2013;26(2):76−80.

5. Abbasi-Montazeri E, Khosravi AD, Feizabadi MM, et al. The prevalence of methicillin resistant Staphylococcus aureus (MRSA) isolates with high-level mupirocin resistance from patients and personnel in a burn center. Burns 2013;39(4):650−4.

6. Deurenberg RH, Vink C, Kalenic S, et al. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007;13(3):222−35.

7. Harmsen D, Claus H, Witte W, et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003;41(12):5442−8.

8. Hirose M, Kobayashi N, Ghosh S, et al. Identification of Staphylocoagulase Genotypes I-X and Discrimination of Type IV and V Subtypes by Multiplex PCR Assay for Clinical Isolates of Staphylococcus aureus. Jpn J Infect Dis 2010;63(4):257−63.

9. Sakai F, Takemoto A, Watanabe S, et al. Multiplex PCRs for assignment of Staphylocoagulase types and subtypes of type VI Staphylocoagulase. J Microbiol Methods 2008;75(2):312−7.

10. Afrough P, Pourmand MR, Sarajian AA, et al. Molecular investigation of Staphylococcus aureus, coa and spa genes in Ahvaz hospitals, staff nose compared with patients clinical samples. Jundishapur J Microbiol 2013;6(4):1−7.

11. Asadollahi P, Farahani NN, Mirzaii M, et al. Distribution of the most prevalent spa types among clinical isolates of methicillin-resistant and-susceptible Staphylococcus aureus around the world: A review. Front Microbiol 2018;9:163.

12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 27th Informational Supplement (M100-S27). 2017.

13. Nezhad RR, Meybodi SM, Rezaee R, et al. Molecular characterization and resistance profile of methicillin resistant Staphylococcus aureus strains isolated from hospitalized patients in intensive care unit, Tehran-Iran. Jundishapur J Microbiol 2017;10(3):e41666.

14. Shahsavan S, Emaneini M, Khoshgnab BN, et al. A high prevalence of mupirocin and macrolide resistance determinant among Staphylococcus aureus strains isolated from burnt patients. Burns 2012;38(3):378−82.

15. Saderi H, Owlia P, Habibi M. Mupirocin resistance among Iranian isolates of Staphylococcus aureus. Med Sci Monit 2008;14(10):BR210−3.

16. Petinaki E, Spiliopoulou I, Kontos F, et al. Clonal dissemination of mupirocin-resistant staphylococci in Greek hospitals. J Antimicrob Chemother 2004;53(1):105−8.

17. Barakat GI, Nabil YM. Correlation of mupirocin resistance with biofilm production in methicillin-resistant Staphylococcus aureus from surgical site infections in a tertiary centre, Egypt. J Glob Antimicrob Resist 2016;4:16−20.

18. Desroches M, Potier J, Laurent F, et al. Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. J Antimicrob Chemother 2013;68(8):1714−7.

19. Ko KS, Lee J-Y, Suh JY, et al. Distribution of major genotypes among methicillin-resistant Staphylococcus aureus clones in Asian countries. J Clin Microbiol 2005;43(1):421−6.

20. Monecke S, Coombs G, Shore AC, et al. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PLoS One 2011;6(4):e17936.

21. Boswihi SS, Udo EE, Al-Sweih N. Shifts in the clonal distribution of methicillin-resistant Staphylococcus aureus in Kuwait hospitals: 1992–2010. PLoS One 2016;11(9):e0162744.

22. Ida T, Okamoto R, Shimauchi C, et al. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol 2001;39(9):3115−21.

23. Ardic N, Sareyyupoglu B, Ozyurt M, et al. Investigation of aminoglycoside modifying enzyme genes in methicillin-resistant staphylococci. Microbiol Res 2006;161(1):49−54.

24. González-Domínguez M, Seral C, Potel C, et al. Genotypic and phenotypic characterization of methicillin-resistant Staphylococcus aureus (MRSA) clones with high-level mupirocin resistance. Diagn Microbiol Infect Dis 2016;85(2):213−7.

25. Gadepalli R, Dhawan B, Mohanty S, et al. Mupirocin resistance in Staphylococcus aureus in an Indian hospital. Diagn Microbiol Infect Dis 2007;58(1):125−7.

26. Park SH, Kim JK, Park K. In vitro antimicrobial activities of fusidic acid and retapamulin against mupirocin-and methicillin-resistant Staphylococcus aureus. Ann Dermatol 2015;27(5):551−6.

27. Janwithayanuchit I, Ngam-Ululert S, Paungmoung P, et al. Epidemiologic study of methicillin-resistant Staphylococcus aureus by coagulase gene polymorphism. Science Asia 2006;32:127−32.

28. Omar NY, Ali HAS, Harfoush RAH, et al. Molecular typing of methicillin resistant Staphylococcus aureus clinical isolates on the basis of protein A and coagulase gene polymorphisms. Int J Microbiol 2014;2014:650328.

29. O’Malley SM, Emele FE, Nwaokorie FO, et al. Molecular typing of antibiotic-resistant Staphylococcus aureus in Nigeria. J Infect Public Health 2015;8(2):187−93.

30. Mirzaii M, Emaneini M, Jabalameli F, et al. Molecular investigation of Staphylococcus aureus isolated from the patients, personnel, air and environment of an ICU in a hospital in Tehran. J Infect Public Health 2015;8(2):202−6.

31. Udo EE, Al-Lawati B-H, Al-Muharmi Z, et al. Genotyping of methicillin-resistant Staphylococcus aureus in the Sultan Qaboos University Hospital, Oman reveals the dominance of Panton–Valentine leucocidin-negative ST6-IV/t304 clone. New Microbes New Infect 2014;2(4):100−5.

32. Monecke S, Skakni L, Hasan R, et al. Characterisation of MRSA strains isolated from patients in a hospital in Riyadh, Kingdom of Saudi Arabia. BMC Microbiol 2012;12:146.

33. Al Laham N, Mediavilla JR, Chen L, et al. MRSA clonal complex 22 strains harboring toxic shock syndrome toxin (TSST-1) are endemic in the primary hospital in Gaza, Palestine. PLoS One 2015;10(3):e0120008.

34. AL-Bakri AG, AL-Hadithi H, Kasabri V, et al. The epidemiology and molecular characterization of methicillin-resistant staphylococci sampled from a healthy Jordanian population. Epidemiol Infect 2013;141(11):2384−91.

35. Wang W-Y, Chiueh T-S, Sun J-R, et al. Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in Taiwan. PLoS One 2012;7(1):e30394.

36. Tristan A, Bes M, Meugnier H, et al. Global distribution of Panton-Valentine leukocidin–positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007;13(4):594−600.

37. Udo EE, Boswihi SS, Al-Sweih N. High prevalence of toxic shock syndrome toxin–producing epidemic methicillin-resistant Staphylococcus aureus 15 (EMRSA-15) strains in Kuwait hospitals. New Microbes New Infect 2016;12(July 2016):24−30.

Table 1

Characteristics of the MRSA strains isolated from burns patients.

SC type	spa type	Toxin genes (No.;%)	Antibiotic resistance profile (No.;%)	Antibiotic resistance genes (No.;%)	Total n (%)
I	t223	tst (2;50)	AP, CD, E, AK, GM, T (2;50)	MecA (4;100), erm(C) (4;100), msr(B) (2;50), erm(A) (3;75), ant (4′)-Ia (4;100), aac (6′)-Ie/aph (2″) (3;75)	4 (4.5)
	t223	tst (2;50)	AP, CD, E, AK, GM, RP, T (2;50)		4 (4.5)

	t852	pvl (1;33.3)	AP, CD, E, AK, GM (2;66.7)	MecA (3;100), ant (4′)-Ia (3;100), aac (6′)-Ie/aph (2″) (3;100), aph (3′)-IIIa(3;100)	3 (3.4)
	t852	pvl (1;33.3)	AP, E, AK, GM, SYN (1;33.3)		3 (3.4)

	t005	-	AP, CD, E, AK, GM, RP, T (1;50)	MecA (2;100), erm(A)(2;100), msr(B) (1;50), tet(M) (2;100), ant (4′)-Ia (2;100),	2 (2.2)
	t005	-	AP, E, T, SYN (1;50)		2 (2.2)

II	t019	eta (2;40)	AP, GM, CD, E (1;20)	MecA (5;100), tet(M) (4;80), ant (4′)-Ia (3;60), aac (6′)-Ie/aph (2″) (4;80), aph (3′)-IIIa(2;40)	5 (5.6)
			AP, GM, RP, T (1;20)
			AP, CD, E, AK, GM, T (3;60)

	t044	pvl (3;75)	AP, CD, E AK, GM (3;75)	MecA (4;100), tet(M) (3;75), ant (4′)-Ia (4;100), aac (6′)-Ie/aph (2″) (3;75), ), aph (3′)-IIIa(4;100)	4 (4.5)
	t044	pvl (3;75)	AP, E, T, SYN (1;25)		4 (4.5)

	t021		AP, E, AK, GM, SYN (2;50)	MecA (4;100), ant (4′)-Ia (4;100), aac (6′)-Ie/aph (2″) (3;75), aph (3′)-IIIa(2;50), erm(A) (2;50) erm(B) (4;100),	4 (4.5)
	t021		AP, CD, E, AK, GM, RP, T (2;50)		4 (4.5)

III	t790	tst (9;56.3)	AP, T, E, MUP (4;25)	MecA (16;100), erm(C) (12;75) msr(A) (10;62.5), ant (4′)-Ia (12;75), aac (6′)-Ie/aph (2″) (10;62.5), aph (3′)-IIIa(9;56.3), tet(M) (14;87.5)	16 (18)
			AP, E, GM, T, SYN, MUP (3;18.8)
			AP, CD, E, AK, GM, RP, T, MUP (4;25)
			AP, CD, E, AK, GM, RP, T (1;6.5)
			AP, E, T, SYN (4;25)

	t064		AP, CD, E, AK, GM, RP, T, MUP (8;80)	MecA (10;100), erm(C) (5;50) erm(A) (8;80), ant (4′)-Ia (9;90), aac (6′)-Ie/aph (2″) (5;50), aph (3′)-IIIa(3;30), tet(M) (9;90), mupA (10;100)	10 (11.2)
	t064		AP, E, GM, T, SYN, MUP (2;20);		10 (11.2)

	t008	pvl (2;33.3)	AP, E, AK, GM, SYN (2;33.3)	MecA (6;100), msr(B)(5;83.3) msr(A) (2;33.3), erm(A) (5;83.3), ant (4′)-Ia (4;66.7), aac (6′)-Ie/aph (2″) (5;83.), aph (3′)-IIIa(4;66.7), mupA (2;33.3)	6 (6.7)
	t008	pvl (2;33.3)	AP, T, E, MUP (4;66.7)		6 (6.7)

	t030	etb (2;20)	AP, GM CD, E (6;60)	MecA (10;100), aac (6′)-Ie/aph (2″) (8;80), aph (3′)-IIIa(6;60), .erm(A) (6;60), msr(B) (8;80), tet(M) (6;60)	10 (11.2)
			AP, GM RP, T (2;20)
			AP, CD, E, AK, GM T (2;20)

IVa	t10795	-	AP, CD, E, AK, GM (2;100)	MecA (2;100), ant (4′)-Ia (2;100),	2 (2.2)

IVb	t421	-	AP, GM CD, E (2;50)	MecA (4;100), erm(B) (3;75), ant (4′)-Ia (4;100)	4 (4.5)
			AP, GM, RP, T (1;25)
			AP, CD, E, AK, GM (1;25)

Va	t005	-	AP, GM, RP, T (1;100)	MecA (1;100), tet(M) (1;100)	1 (1.1)

VI	t223	tst (3;100)	AP, CD, E, AK, GM, T (2;66.7)	MecA (3;100), aph (3′)-IIIa(3;100)	3 (3.4)
	t223	tst (3;100)	AP, CD, E, AK, GM (1;33.3)	MecA (3;100), aph (3′)-IIIa(3;100)	3 (3.4)

	t421	-	AP, CD, E, AK, GM (1;100)	MecA (1;100), ), aac (6′)-Ie/aph (2″) (1;100), erm(B) (1;100),	1 (1.1)

VII	t019	-	AP, GM, RP, T (1;100)	MecA (1;100), erm(B) (1;100),	1 (1.1)

VIII	t852	pvl (1;20)	AP, E, AK, GM, SYN (3;60)	MecA (5;100), ), aac (6′)-Ie/aph (2″) (4;80), aph (3′)-IIIa(5;100), erm(B) (4;80),	5 (5.6)
	t852	pvl (1;20)	AP, GM, RP, T (2;40)		5 (5.6)

	t044	pvl (2;40)	AP, E, AK, GM, SYN (2;40)	MecA (5;100), erm(B) (5;80),	5 (5.6)
	t044	pvl (2;40)	AP, GM, RP, T (3;60)	MecA (5;100), erm(B) (5;80),	5 (5.6)

X	t064	-	AP, E, AK, GM, SYN (2;100)	MecA (2;100), ant (4′)-Ia (2;100)	2 (2.2)

	t421	-	AP, GM, RP, T (1;100)	MecA (1;100), ant (4′)-Ia (1;100)	1 (1.1)

AP = ampicillin; CD = clindamycin; E = erythromycin; AK = amikacin; GM = gentamicin; MRSA = methicillin-resistant Staphylococcus aureus; MUP = mupirocin; RP = rifampicin; SYN = quinupristin-dalfopristin; T = tetracycline.